ReviewEuropean journal of nuclear medicine and molecular imaging2026
Cost-effectiveness of preoperative parathyroid imaging in primary hyperparathyroidism: A synthesis of eight health-economic analyses.
Review in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePreoperative localisation of hyperfunctioning parathyroid tissue underpins minimally invasive parathyroidectomy (MIP) in primary hyperparathyroidism (pHPT). Cervical ultrasound (cUS), [⁹⁹ᵐTc]Tc-sestamibi ([⁹⁹ᵐTc]Tc-MIBI) single-photon emission computed tomography/computed tomography (SPECT/CT), and choline positron emission tomography/computed tomography (PET/CT) differ in diagnostic accuracy and cost. Whether choline PET/CT should be reserved for second-line use or implemented first-line remains debated. We synthesised cost-effectiveness evidence from recent health-economic analyses across different healthcare systems.
methodsIn this narrative review, MEDLINE (via PubMed) was searched for original health-economic analyses evaluating preoperative parathyroid imaging in pHPT published 2022-2026, supplemented by reference-list screening. Eight studies were included. The modelling framework, analytical perspective, imaging comparators, base-case costs, incremental cost-effectiveness ratios (ICERs), incremental cost-utility ratios (ICURs) and willingness-to-pay (WTP) thresholds were extracted.
resultsThe included studies comprised two retrospective cohorts, three decision trees, one Markov model, one cohort-level state-transition model, and one randomised controlled trial (APACH2). Across most healthcare settings, first-line choline PET/CT was more cost-effective than [⁹⁹ᵐTc]Tc-MIBI-based pathways. Reported ICERs included €471 per additional surgical cure (APACH2), US$470 per quality-adjusted life-year (QALY) (USA), €12,650 per QALY (France), and Colombian pesos (COP) 101,727-277,037 per additional cure. At one Dutch centre, [¹¹C]choline PET/CT was a dominant strategy (ICUR -€18,846/QALY), while a Spanish cohort demonstrated approximately 19% lower per-patient costs with PET-only imaging. PET tariff and local [⁹⁹ᵐTc]Tc-MIBI performance were the principal determinants of cost-effectiveness.
conclusionsFirst-line choline PET/CT is cost-effective compared with [⁹⁹ᵐTc]Tc-MIBI-based imaging pathways across most WTP thresholds. Implementation should be guided by local PET reimbursement and [⁹⁹ᵐTc]Tc-MIBI performance.
Indexed as
Identifiers
42566021What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.